Who Makes Rogue Nicotine Pouches? Company & FDA Status

Rogue nicotine pouches are produced through Rogue Holdings, LLC, a joint venture between Swisher International and Avema Pharma Solutions. Avema manufactures and supplies Rogue products, while Swisher markets and distributes them. Rogue’s official product pages list its pouches as U.S.-made with domestic and imported ingredients. As of this review, Rogue does not appear on the FDA’s list of authorized nicotine pouch products; a pending application is not a marketing authorization.

• Rogue is made and supplied by Rogue Holdings, LLC, with Avema Pharma Solutions handling manufacturing and supply and Swisher International handling marketing and distribution.
• PMTA review matters more than flavor count when checking whether a specific SKU is authorized.
• Safe storage and responsible handling help reduce acute household risks; FDA oversight does not make nicotine products risk-free.

The Flavor Illusion vs. The PMTA Reality

Flavor count is not a substitute for the FDA's product-specific premarket review, which evaluates whether marketing a product would be appropriate for the protection of public health. Rogue’s current official shop lists 12 pouch flavors, each offered in 3 mg and 6 mg strengths.

Here's the thing about that shortcut. The brain treats "cleaner alternative" marketing as a verified proxy for safety, and it simply is not one. Flavor variety tells you nothing about what the toxicological data says. Rogue’s official listings currently show 12 pouch flavors: Wintergreen, Peppermint, Spearmint, Mango, Citrus, Berry, Apple, Cinnamon, Original, Bold, Smooth, and Honey-Lemon. Flavor count is a product attribute, not evidence of safety or FDA authorization.

For adults age 21 and older only. Contains nicotine. Nicotine is an addictive chemical.

So before we evaluate any safety profile, we trace the corporate filings. The question that actually matters — who makes rogue nicotine pouches — sits upstream of the flavor wall, in supply-chain paperwork most buyers never open.

Tracing the Supply Chain: Who Makes Rogue Nicotine Pouches

Rogue Holdings, LLC is a joint venture between Swisher International and Avema Pharma Solutions, an affiliate of PL Developments. Avema manufactures and supplies Rogue products, while Swisher markets and distributes them. Rogue’s official pages describe the pouches as tobacco-leaf-free, spit-free and sugar-free; they use nicotine polacrilex, come in 3 mg and 6 mg strengths, contain 20 pouches per can, and are made in the USA with domestic and imported ingredients.

Swisher has a long-established cigar business, while Rogue Holdings operates in the modern oral nicotine category. That background explains Swisher’s marketing and distribution role, but it does not change Avema’s stated manufacturing and supply role.

Knowing the manufacturer is only the baseline, though. Here's where policy professionals get tripped up. Corporate identity answers "who," but it doesn't answer "is this legally cleared." The real test lives downstream, in whether the product survives the Tobacco Control Act's safety mandates. Under current FDA requirements, a new tobacco product generally must receive written marketing authorization before it may be lawfully marketed. A PMTA must contain sufficient scientific evidence for FDA to determine whether marketing the specific product would be appropriate for the protection of public health.

Understanding Household Storage and Safety

Because nicotine pouches do not involve combustion, they do not produce smoke during use; they still require responsible household storage. This is the part the flavor-first crowd skips. The FDA explicitly advises secure storage away from children and points to the Poison Control HELP line (1-800-222-1222) for accidental ingestion. Smoke-free does not mean risk-free.

Regulators emphasize the importance of responsible storage, ensuring adult-only products are kept securely away from unintended audiences. Proper storage and adherence to age-restricted sales are standard best practices for all adult-focused nicotine products.

According to current Centers for Disease Control and Prevention guidance, more research is needed to understand the short- and long-term health effects of nicotine pouches. Nicotine is highly addictive, and people who do not currently use tobacco products should not start.

Household exposure risk and premarket review are distinct regulatory issues. FDA evaluates new tobacco products individually and separately advises consumers to store nicotine pouches securely away from children and pets.

The PMTA Pathway: Why Science Outweighs Marketing

Whether a new nicotine pouch may be lawfully marketed in the United States depends on FDA marketing authorization, not on how many flavors it lists. The agency does not authorize a product based on flavor count alone; it evaluates the product-specific evidence, including ingredient and toxicological information.

A PMTA must provide sufficient scientific evidence for FDA to determine whether marketing the product would be appropriate for the protection of public health. The evidence may include product chemistry, toxicology, use behavior and other product-specific information. A 2023 study authored by Swedish Match researchers compared two ZYN pouch products with selected smokeless-tobacco and nicotine-replacement products; it did not evaluate Rogue and should not be generalized to every pouch brand.

Marketing claims do not substitute for FDA marketing authorization, which is based on the evidence for each specific product.

So how does Rogue's regulatory posture compare with authorized competitors? FDA-authorized products and unauthorized products—including some with pending applications that may fall under current enforcement-discretion priorities—can both appear at retail, but they do not have the same legal status.

The Competitive Environment: Rogue vs. FDA Authorized Nicotine Pouches

While brands like ZYN and on! PLUS have secured specific FDA authorizations for certain SKUs, the broader market remains entangled in ongoing PMTA reviews. Authorization is granular. It attaches to individual products, not to a whole brand, and the SKU-count picture reflects that fragmentation.

Here's a clean way to map the regulatory states without confusing shoppers.

FDA authorization applies to specific products and does not mean a product is safe or ‘FDA approved.’ FDA’s current authorized nicotine-pouch list includes specified ZYN and on! PLUS products and does not list Rogue. In a 2023 public filing, Rogue Holdings stated that its products were covered by timely filed, pending PMTAs; that company statement is not an FDA marketing order and does not establish the present status of every Rogue SKU.

The CDC Reality and Evidence-Based Oversight

Public health organizations like the CDC correctly note that these products contain nicotine, which is an addictive substance. I'll say plainly: I sit on the harm-reduction side of this debate, and from here, evidence-based standards are essential.

Nicotine pouches free of tobacco leaf still deliver nicotine and still carry a risk of addiction, and the long-term data remains open, according to current Centers for Disease Control and Prevention guidance. That's not a reason for panic. It's a reason for structure. Evidence-based oversight is the only response that respects both adult consumer demand and the public-health risk at the same time.

The World Health Organization (2023) report reviews nicotine-pouch characteristics, use, harmfulness and regulation and notes that evidence remains limited. In the United States, product claims and regulatory status should be checked against current FDA records rather than inferred from packaging or retail availability.

For adults age 21 and older only. Contains nicotine. Nicotine is an addictive chemical.

So here's my parting judgment as someone who reads the filings retailers cite. When auditing who makes Rogue nicotine pouches, distinguish the roles: Rogue Holdings operates the brand, Avema manufactures and supplies the products, and Swisher markets and distributes them. Then check the exact product against current FDA authorization records. Quality in oral nicotine rests on responsible manufacturing and disclosed toxicological data, not just on how good the tin looks in your hand.